ngx267
Small moleculeexperimental
Clinical trial activity
2 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2008 (NCT00637793)
Timeline
Indications
Mechanism of action
CHRM1 agonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- af267b
- af267b
- af267b
- ngx267
- ngx267
- ngx267
- ngx267
- (s)-2-ethyl-8-methyl-1-thia-4,8-diazaspiro(4.5)decan-3-one
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06995573 | Phase 1/Phase 2 (Phase 2) | Jun 30, 2025 | NeuroScios GmbH, NSC-Therapeutics |
| NCT00637793 | Phase 2 | Feb 1, 2008 | Altoona Center for Clinical Research, TorreyPines Therapeutics, University of Pennsylvania, Walter F. Chase MD. PA |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Altoona Center for Clinical Research | For profit | 1 | 0 | 1 | 2008 |
| NeuroScios GmbH | For profit | 1 | 0 | 1 | 2025 |
| NSC-Therapeutics | For profit | 1 | 1 | 1 | 2025 |
| TorreyPines Therapeutics | For profit | 1 | 1 | 1 | 2008 |
| University of Pennsylvania | Academic/Hospital | 1 | 0 | 1 | 2008 |
| Walter F. Chase MD. PA | Academic/Hospital | 1 | 0 | 1 | 2008 |
6 organizations
Page 1 / 1